Anti-influenza virus effects of both live and non-live<i>Lactobacillus acidophilus</i>L-92 accompanied by the activation of innate immunity

Goto, Hiroaki; Sagitani, Atsuhiro; Ashida, Nobuhisa; Kato, Shinobu; Hirota, Toshiyuki; Shinoda, Tadashi; Yamamoto, Naoyuki

doi:10.1017/s0007114513001104

Cited by 75 publications

(42 citation statements)

References 43 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2). In line with our hypothesis, some previous studies reported that administration of probiotics showed reduction in pulmonary virus titres at the same time as alleviation of clinical symptoms during the later stages of IFV infection (Iwabuchi et al 2011;Kawase et al 2011;Goto et al 2013). Thus, oral administration of KB290 may induce a reduction in the pulmonary virus titres at a later stage of IFV infection.…”

Section: Resultssupporting

confidence: 91%

See 1 more Smart Citation

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Waki¹,

Yajima²,

Suganuma³

et al. 2013

Lett Appl Microbiol

View full text Add to dashboard Cite

Significance and Impact of the Study: This study demonstrated that oral administration of Lactobacillus brevis KB290 (KB290), a probiotic strain derived from a Japanese traditional pickle, could protect against influenza virus (IFV) infection in mice. Our results demonstrated that continual intake of KB290 for 14 days prior to IFV infection alleviated clinical symptoms such as loss of body weight and deterioration in observational physical conditions induced by the infection. The beneficial effects of KB290 consumption may have been elicited by the long-lasting enhancement of interferon-a production and the augmentation of IFV-specific immunoglobulin A production. AbstractLactobacillus brevis KB290 (KB290), isolated from a traditional Japanese pickle 'Suguki', has been reported to have immunomodulatory effects. We investigated whether oral administration of KB290 has protective effects against influenza virus (IFV) infection in mice. After 14 days of administration of lyophilized KB290 suspended in phosphate-buffered saline by oral gavage, BALB/c mice were intranasally infected with 2 9 MLD 50 (50% mouse lethal dose) of IFV A/PR/8/34 (H1N1). Prophylactically administered KB290 significantly alleviated the loss of body weight and the deterioration in observational physical conditions induced by the infection. In addition, 7 days after infection, the levels of IFV-specific immunoglobulin (Ig)A in bronchoalveolar lavage fluid were significantly increased in mice fed KB290 compared with controls. Moreover, there was a significant elevation of serum interferon (IFN)-a in KB290 group mice, even at three and 7 days after infection, despite the administration of KB290 being stopped before IFV infection. Our results demonstrated that oral administration of KB290 before infection could alleviate IFV-induced clinical symptoms. Alleviation of clinical symptoms by KB290 consumption may have been induced by long-lasting enhancement of IFN-a production and the augmentation of IFV-specific IgA production.

show abstract

Section: Resultssupporting

confidence: 91%

“…; Goto et al . ). Thus, oral administration of KB290 may induce a reduction in the pulmonary virus titres at a later stage of IFV infection.…”

Section: Resultsmentioning

confidence: 97%

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Waki¹,

Yajima²,

Suganuma³

et al. 2013

Lett Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…Interestingly, oral administration of at least three distinct Lactobacillus strains have also been reported as effective against the lethal sequelae of influenza [34 - 36]. These results are significantly at odds with our findings with PVM, in which we document that prolonged oral administration of L. plantarum has no impact whatsoever on survival (Fig.…”

Section: Discussioncontrasting

confidence: 90%

B Cells Are Not Essential for Lactobacillus-Mediated Protection against Lethal Pneumovirus Infection

Percopo

Dyer

Garcia-Crespo

et al. 2014

The Journal of Immunology

View full text Add to dashboard Cite

We have shown previously that priming of respiratory mucosa with live Lactobacillus species promotes robust and prolonged survival from an otherwise lethal infection with pneumonia virus of mice (PVM), a property known as heterologous immunity. Lactobacillus-priming results in a moderate reduction in virus recovery and a dramatic reduction in virus-induced proinflammatory cytokine production; the precise mechanisms underlying these findings remain to be elucidated. As B cells have been shown to promote heterologous immunity against respiratory virus pathogens under similar conditions, here we explore the role of B cells in Lactobacillus-mediated protection against acute pneumovirus infection. We found that Lactobacillus-primed mice feature elevated levels of airway immunoglobulins IgG, IgA and IgM and lung tissues with dense, B cell (B220+) enriched peribronchial and perivascular infiltrates with germinal centers consistent with descriptions of bronchus-associated lymphoid tissue. No B cells were detected in lung tissue of Lactobacillus-primed B-cell deficient μMT mice or Jh mice, and Lactobacillus-primed μMT mice had no characteristic infiltrates or airway immunoglobulins. Nonetheless, we observed diminished virus recovery and profound suppression of virus-induced proinflammatory cytokines CCL2, IFN-gamma, and CXCL10 in both wild-type and Lactobacillus-primed μMT mice. Furthermore, L. plantarum-primed, B-cell deficient μMT and Jh mice were fully protected from an otherwise lethal PVM infection, as were their respective wild-types. We conclude that B cells are dispensable for Lactobacillus-mediated heterologous immunity and were not crucial for promoting survival in response to an otherwise lethal pneumovirus infection.

show abstract

“…Using this newly developed method, a human trial of the anti-influenza effect of yogurt containing Lactobacillus acidophilus L-92 was conducted, which was previously shown to have an anti-viral effect in laboratory animals [3] and anti-allergy properties in both humans and animals [4], [5], [13]. In such a human trial, recruiting a significant sample size of subjects is problematic because the average percentage of symptomatic influenza patients is usually less than 10% of the general population.…”

Section: Resultsmentioning

confidence: 99%

“…According to the above data, it seems that the developed method was applicable not only in detecting influenza virus at early stage, but could evaluate preventive effects on virus infection in the development of drugs or functional foods. As for L-92, it was recently demonstrated that continuous oral administration of L-92 for 2 weeks suppressed the viral titer and activated NK cells in lungs of mice infected with influenza virus [3]. Therefore, L-92 may have the potential to promote vigorous host immune responses.…”

Section: Resultsmentioning

confidence: 99%

Highly sensitive detection of influenza virus in saliva by real-time PCR method using sugar chain-immobilized gold nanoparticles; application to clinical studies

Suda

Nagatomo

Yokoyama

et al. 2015

Biotechnology Reports

Self Cite

View full text Add to dashboard Cite

show abstract

Anti-influenza virus effects of both live and non-liveLactobacillus acidophilusL-92 accompanied by the activation of innate immunity

Cited by 75 publications

References 43 publications

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

Oral administration ofLactobacillus brevisKB290 to mice alleviates clinical symptoms following influenza virus infection

B Cells Are Not Essential for Lactobacillus-Mediated Protection against Lethal Pneumovirus Infection

Highly sensitive detection of influenza virus in saliva by real-time PCR method using sugar chain-immobilized gold nanoparticles; application to clinical studies

Contact Info

Product

Resources

About